









Markets
/
Stocks
/
nasdaq-prof
/

Profound Medical Corp

PROF

5.850USD

-0.010-0.17%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

175.81MMarket Cap

LossP/E TTM



Profound Medical Corp

5.850

-0.010-0.17%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Profound Medical Corp

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Profound Medical Corp's Score

Industry at a Glance

Industry Ranking

102 / 210

Overall Ranking

247 / 4615

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

11.313

Target Price

+93.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Profound Medical Corp Highlights

StrengthsRisks

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 59.86% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.68M.

Overvalued

The company’s latest PE is -4.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.80M shares, decreasing 8.01% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.38.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.32, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.21M, representing a year-over-year decrease of 0.99%, while its net profit experienced a year-over-year decrease of 126.84%.

Score

Industry at a Glance

Previous score

6.32

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.37

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Profound Medical Corp's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.49, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -4.03, which is -33.85% below the recent high of -2.66 and -182.22% above the recent low of -11.37.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 102/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.80, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Profound Medical Corp is 11.12, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

11.313

Target Price

+93.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Profound Medical Corp

PROF

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.77, which is higher than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 6.63 and the support level at 5.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.77

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.058

Neutral

RSI(14)

53.749

Neutral

STOCH(KDJ)(9,3,3)

59.130

Neutral

ATR(14)

0.367

Low Volatility

CCI(14)

8.992

Neutral

Williams %R

39.748

Buy

TRIX(12,20)

0.443

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.926

Sell

MA10

5.908

Sell

MA20

5.799

Buy

MA50

5.192

Buy

MA100

5.403

Buy

MA200

5.641

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gagnon (Neil)

3.35M

+531.45%

Fidelity Investments Canada ULC

1.89M

+3.86%

Gagnon Securities LLC

1.75M

+3.08%

BDC Venture Capital

1.22M

Letko, Brosseau & Associates Inc.

1.20M

-0.30%

Daseke Don R

1.10M

Gagnon Advisors, LLC

896.67K

Raymond James Financial Services Advisors, Inc.

862.66K

+4.14%

Timelo Investment Management Inc.

840.66K

-15.17%

Royce Investment Partners

Star Investors

764.91K

+0.41%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.11, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.